O T C
PAOG Releases CBD Nutraceutical 2021 Product Launch Preview Highlighting PURA EVERx Partnership, ALKM Co-Packing and USMJ Distribution

  Sandusky, OH, May 7, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today released a preview of the company’s plan to launch a CBD Nutraceuticals line of products.  PAOG’s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments.

PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday

  Sandusky, OH, May 5, 2021 – OTC PR WIRE — PAO Group, Inc. (USOTC: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived

PAOG 2021 CBD Nutraceutical Sales Rollout Plan Presentation Scheduled This Friday

  Sandusky, OH, May 3, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today announced plans to present the company’s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive

PAOG Announces Opportunity To Expand CBD Pharmaceutical Research

  Sandusky, OH, April 13, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today released a management update on the company’s ongoing CBD Pharmaceutical Development Program. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived

PAOG CBD Pharmaceutical Development Update Coming Tomorrow, Tuesday April 13, 2021

  Sandusky, OH, April 12, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today confirmed a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is

PAOG Advances CBD Pharmaceutical Developments Backed By US Patent

  Sandusky, OH, April 8, 2021 – OTC PR WIRE —  PAO Group, Inc. (OTC Pink: PAOG) today announced a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is

PAOG Targets September 2021 To Introduce CBD Nutraceuticals To Market Co-Packed By ALKM and Marketed Through USMJ

  Sandusky, OH, March 16, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today released details on the company’s nutraceutical developments initiative following last week’s introduction of adding CBD RELAX-RX to existing CBD RespRx developments.  The details today are highlighted by the company’s September 2021 go-to-market target date with nutraceutical co-packing

PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market

  Sandusky, OH, March 8, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The company recently announced plans to produce a variety of nutraceuticals

PAOG Expects To Realize Revenue This Year From New CBD Nutraceuticals

  Sandusky, OH, February 18, 2021 – OTC PR WIRE — PAO Group, Inc. (OTC Pink: PAOG) today highlighted the company’s anticipated revenue expected this year from its CBD nutraceutical expansion.  Earlier this week, the company published an online, multimedia presentation detailing the company’s CBD nutraceutical development expansion plans.  The presentation includes details on PAOG’s

PAOG Announces CBD Nutraceuticals Expansion Plan Multimedia Presentation

Sandusky, OH, February 16, 2021 –  OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today published an online, multimedia presentation detailing the company’s CBD nutraceutical development expansion plans. The CBD nutraceutical development expansion plans are anticipated to generate revenue beginning this year, in 2021 adding to the company’s previously announced anticipated revenue for

Recent Posts

Recent Posts

Contact Us

All Rights Reserved © 2019